Concordance data for PD-L1 testing for triple-negative breast cancer for KEYTRUDA® (pembrolizumab)
Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) [External links]
PDF, 850 KB
Downloadable infographic demonstrating an overview of testing for PD-L1 in triple-negative breast cancer. It describes the current concordance data between assays by scoring algorithms and cut offs. Please see the Summary of Product Characteristics below for further information regarding KEYTRUDA (pembrolizumab).
to keep updated with the latest education materials in PD-L1 testing
Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland)
By clicking the links above you will leave the MSD Connect website and be taken to the emc PI portal website